Faron Pharmaceuticals Oy (LON:FARN) Hits New 52-Week Low – Here’s What Happened

Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) hit a new 52-week low on Tuesday. The company traded as low as GBX 28 and last traded at GBX 28, with a volume of 5,350 shares. The stock had previously closed at GBX 29.

Faron Pharmaceuticals Oy Stock Performance

The stock has a market capitalization of £58.02 million, a price-to-earnings ratio of -2.48 and a beta of 1.12. The company has a 50 day simple moving average of GBX 33.66 and a 200-day simple moving average of GBX 45.20. The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15.

About Faron Pharmaceuticals Oy

(Get Free Report)

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

Featured Articles

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.